CO6150161A2 - Ciclopenta [d] pirimidinas hidroxiladas y metoxiladas como inhibidores de la proteina kinasa akt - Google Patents

Ciclopenta [d] pirimidinas hidroxiladas y metoxiladas como inhibidores de la proteina kinasa akt

Info

Publication number: CO6150161A2
Authority: CO; Colombia
Prior art keywords: alkyl; optionally substituted; cycloalkyl; phenyl; metoxylated
Prior art date: 2006-07-06

Application number

CO09010508A

Other languages

English (en)

Spanish (es)

Inventor

Ian S Mitchell

James Blake

Rui Xu

Nicholas C Kallan

Dengming Xiao

Keith Lee Spencer

Josef Bencsik

Jun Liang

Brian Safina

Birong Zhang

Christine Chabot

Steven Do

Eli M Wallace

Anna Banka

Stephen Schlachter

Original Assignee

Array Biopharma Inc

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-06

Filing date

2009-02-04

Publication date

2010-04-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6150161(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-04 Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc

2010-04-20 Publication of CO6150161A2 publication Critical patent/CO6150161A2/es

Links

239000003112 inhibitor Substances 0.000 title 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 5
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
229910052794 bromium Inorganic materials 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
229910052731 fluorine Inorganic materials 0.000 abstract 1
VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000002883 imidazolyl group Chemical group 0.000 abstract 1
229910052740 iodine Inorganic materials 0.000 abstract 1
239000002207 metabolite Substances 0.000 abstract 1
125000002757 morpholinyl group Chemical group 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
125000003566 oxetanyl group Chemical group 0.000 abstract 1
125000004043 oxo group Chemical group O=* 0.000 abstract 1
125000003386 piperidinyl group Chemical group 0.000 abstract 1
125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
229920002554 vinyl polymer Polymers 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)

CO09010508A 2006-07-06 2009-02-04 Ciclopenta [d] pirimidinas hidroxiladas y metoxiladas como inhibidores de la proteina kinasa akt CO6150161A2 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US81871806P	2006-07-06	2006-07-06

Publications (1)

Publication Number	Publication Date
CO6150161A2 true CO6150161A2 (es)	2010-04-20

Family

ID=38686743

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CO09010508A CO6150161A2 (es)	2006-07-06	2009-02-04	Ciclopenta [d] pirimidinas hidroxiladas y metoxiladas como inhibidores de la proteina kinasa akt

Country Status (34)

Country	Link
EP (4)	EP2402325B1 (2)
JP (4)	JP5266216B2 (2)
KR (5)	KR20140093291A (2)
CN (2)	CN101578273B (2)
AR (3)	AR061842A1 (2)
AT (1)	ATE524447T1 (2)
AU (1)	AU2007269060B2 (2)
BR (3)	BR122013028005B8 (2)
CA (2)	CA2656622C (2)
CL (1)	CL2007001993A1 (2)
CO (1)	CO6150161A2 (2)
CR (1)	CR10600A (2)
CY (1)	CY1112117T1 (2)
DK (2)	DK2049501T3 (2)
ES (3)	ES2372774T3 (2)
HR (1)	HRP20110908T1 (2)
HU (1)	HUE026237T2 (2)
IL (2)	IL196028A (2)
IN (1)	IN2014KN02886A (2)
MA (1)	MA31655B1 (2)
MX (4)	MX366319B (2)
MY (1)	MY147364A (2)
NO (1)	NO342346B1 (2)
NZ (3)	NZ610633A (2)
PL (2)	PL2402325T3 (2)
PT (1)	PT2049501E (2)
RS (1)	RS52212B (2)
RU (2)	RU2478632C2 (2)
SG (4)	SG188905A1 (2)
SI (2)	SI2049501T1 (2)
TW (2)	TWI402266B (2)
UA (1)	UA95641C2 (2)
WO (1)	WO2008006040A1 (2)
ZA (1)	ZA200900070B (2)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE532789T1 (de)	2006-07-06	2011-11-15	Array Biopharma Inc	Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US8063050B2 (en) *	2006-07-06	2011-11-22	Array Biopharma Inc.	Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) *	2006-07-06	2011-08-25	Эррей Биофарма Инк.	Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
CA2656566C (en)	2006-07-06	2014-06-17	Array Biopharma Inc.	Dihydrofuro pyrimidines as akt protein kinase inhibitors
ATE523499T1 (de)	2006-07-06	2011-09-15	Array Biopharma Inc	Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
US20110135569A1 (en)	2007-03-20	2011-06-09	Peak Biosciences Inc.	Method for therapeutic administration of radionucleosides
WO2009006567A2 (en)	2007-07-05	2009-01-08	Array Biopharma Inc.	Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8846683B2 (en)	2007-07-05	2014-09-30	Array Biopharma, Inc.	Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en)	2007-07-05	2016-08-09	Array Biopharma Inc.	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101918373B (zh)	2007-07-05	2013-06-05	阵列生物制药公司	作为akt蛋白激酶抑制剂的嘧啶基环戊烷
EP2240455B1 (en)	2008-01-09	2012-12-26	Array Biopharma, Inc.	Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
TW200940542A (en)	2008-01-09	2009-10-01	Array Biopharma Inc	Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101970415A (zh) *	2008-01-09	2011-02-09	阵列生物制药公司	作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶
ES2422733T3 (es) *	2008-01-09	2013-09-13	Array Biopharma Inc	Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
MX2013007171A (es) *	2010-12-23	2013-11-04	Genentech Inc	Inductor de autofagia y terapia de combinacion inhibidora para el tratamiento de neoplasias.
PL2694959T3 (pl) *	2011-04-01	2020-05-18	Genentech, Inc.	Biomarkery do przewidywania wrażliwości w leczeniu nowotworu złośliwego
RU2013148817A (ru)	2011-04-01	2015-05-10	Дженентек, Инк.	Комбинации соединений-ингибиторов акт и мек и способы их применения
WO2012135781A1 (en) *	2011-04-01	2012-10-04	Genentech, Inc.	Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
EP2850200A1 (en) *	2012-05-17	2015-03-25	Genentech, Inc.	Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
HRP20180948T1 (hr)	2012-05-17	2018-08-10	Genentech, Inc.	Postupak za proizvodnju aminokiselinskih spojeva
ES2588878T3 (es)	2012-05-17	2016-11-07	Array Biopharma, Inc.	Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
KR102678074B1 (ko)	2012-05-17	2024-06-26	제넨테크, 인크.	무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
US9416110B2 (en)	2012-05-17	2016-08-16	Array Biopharma Inc.	Process for making hydroxylated cyclopentylpyrimidine compounds
US20150258127A1 (en)	2012-10-31	2015-09-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preventing antiphospholipid syndrome (aps)
JP2016502974A (ja) *	2012-12-07	2016-02-01	ザジェネラルホスピタルコーポレイション	Ｐｉ３ｋ／ａｋｔ阻害剤化合物とｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用
JP6340162B2 (ja)	2012-12-20	2018-06-06	日東電工株式会社	アポトーシス誘導剤
SI3068770T1 (sl)	2013-11-15	2020-02-28	F. Hoffmann-La Roche Ag	Postopki za pripravo pirimidinilciklopentanskih spojin
RU2732404C2 (ru) *	2014-09-26	2020-09-16	Ф. Хоффманн-Ля Рош Аг	СПОСОБЫ ПОЛУЧЕНИЯ (ЦИКЛОПЕНТИЛ[d]ПИРИМИДИН-4-ИЛ)ПИПЕРАЗИНОВЫХ СОЕДИНЕНИЙ
BR112019002007B1 (pt)	2016-08-10	2024-01-16	F. Hoffmann-La Roche Ag	Composição farmacêutica e uso de uma composição farmacêutica
KR20190084063A (ko)	2016-10-28	2019-07-15	이칸 스쿨 오브 메디슨 엣 마운트 시나이	Ｅｚｈ２-매개성 암 치료용 조성물 및 방법
JP2021515013A (ja) *	2018-03-06	2021-06-17	アイカーンスクールオブメディスンアットマウントシナイ	セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法
EP3810145A4 (en)	2018-06-21	2022-06-01	Icahn School of Medicine at Mount Sinai	Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
TWI719765B (zh)	2018-12-19	2021-02-21	美商建南德克公司	使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療
US20220040324A1 (en)	2018-12-21	2022-02-10	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
AU2020214258B2 (en)	2019-01-29	2025-08-28	Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.	AKT inhibitor
WO2020201073A1 (en)	2019-03-29	2020-10-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
JP7667742B2 (ja) *	2019-04-09	2025-04-23	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	Ａｔｐ競合性ａｋｔ阻害剤ｇｄｃ－００６８とｅ３リガーゼリガンドとの結合によるａｋｔの分解および使用方法
JP7503851B2 (ja)	2019-05-06	2024-06-21	アイカーンスクールオブメディスンアットマウントシナイ	Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物
CN115397815B (zh) *	2020-03-17	2024-06-14	江苏恒瑞医药股份有限公司	稠合二环类衍生物、其制备方法及其在医药上的应用
US12103924B2 (en)	2020-06-01	2024-10-01	Icahn School Of Medicine At Mount Sinai	Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CN115916758A (zh)	2020-06-16	2023-04-04	豪夫迈·罗氏有限公司	用于制备羟基化环戊基嘧啶化合物的方法
US20230286979A1 (en)	2020-07-22	2023-09-14	Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.	Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof
TWI750905B (zh) *	2020-11-19	2021-12-21	財團法人國家衛生研究院	噻唑化合物作為蛋白質激酶抑制劑
KR102689151B1 (ko) *	2021-09-06	2024-07-29	연세대학교 산학협력단	Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) *	2021-09-15	2023-03-23	Teva Pharmaceuticals International Gmbh	Solid state forms of ipatasertib citrate
CN113788834B (zh) *	2021-09-18	2022-11-29	河南奥思恩医药科技有限公司	2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
CN117677614A (zh) *	2021-12-17	2024-03-08	中国医药研究开发中心有限公司	具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
JP2025510910A (ja)	2022-03-31	2025-04-15	アストラゼネカ・アクチエボラーグ	癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤
IL320302A (en)	2022-10-17	2025-06-01	Astrazeneca Ab	SERD combinations for cancer treatment
WO2024100236A1 (en)	2022-11-11	2024-05-16	Astrazeneca Ab	Combination therapies for the treatment of cancer
CN120712346A (zh)	2023-01-31	2025-09-26	豪夫迈·罗氏有限公司	具有增加的酮还原酶活性的突变型酮还原酶以及涉及其的方法和用途
EP4643858A1 (en)	2024-04-29	2025-11-05	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical composition for the treatment of uterine disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
NL7112938A (2) *	1970-09-30	1972-04-05
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
BR9807100A (pt) *	1997-01-08	2000-04-25	Hoffamann La Roche Ag F	Benzo[e]isoindóis e benzo[h]isoquinolinas tricìclicos
ES2152902B1 (es) *	1999-07-27	2001-08-16	Medichem Sa	Procedimiento de obtencion de venlafaxina
PT1315715E (pt) *	2000-08-18	2008-10-30	Millennium Pharm Inc	Derivados de quianazolina utilizados como inibidores de quinase
WO2002022605A1 (en) *	2000-09-15	2002-03-21	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
WO2002083083A2 (en) *	2001-03-30	2002-10-24	King Pharmaceuticals, Inc.	Pharmaceutically active compounds and methods of use
US20050107404A1 (en) *	2001-12-06	2005-05-19	Fraley Mark E.	Mitotic kinesin inhibitors
EP1470121B1 (en) *	2002-01-23	2012-07-11	Bayer HealthCare LLC	Pyrimidine derivatives as rho-kinase inhibitors
TW200306819A (en) *	2002-01-25	2003-12-01	Vertex Pharma	Indazole compounds useful as protein kinase inhibitors
NZ590160A (en)	2003-11-21	2012-07-27	Array Biopharma Inc	AKT protein kinase inhibitors
WO2005105780A2 (en) *	2004-04-28	2005-11-10	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of rock and other protein kinases
WO2005113762A1 (en)	2004-05-18	2005-12-01	Pfizer Products Inc.	CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
CA2600745A1 (en) *	2005-03-03	2006-09-08	The Burnham Institute For Medical Research	Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
ATE532789T1 (de) *	2006-07-06	2011-11-15	Array Biopharma Inc	Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
ATE523499T1 (de) *	2006-07-06	2011-09-15	Array Biopharma Inc	Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
UA95641C2 (xx) *	2006-07-06	2011-08-25	Эррей Биофарма Инк.	Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы

2007
- 2007-05-07 UA UAA200900764A patent/UA95641C2/ru unknown
- 2007-07-05 NZ NZ610633A patent/NZ610633A/en unknown
- 2007-07-05 EP EP11166125.2A patent/EP2402325B1/en active Active
- 2007-07-05 DK DK07799337.6T patent/DK2049501T3/da active
- 2007-07-05 WO PCT/US2007/072885 patent/WO2008006040A1/en not_active Ceased
- 2007-07-05 BR BR122013028005A patent/BR122013028005B8/pt active IP Right Grant
- 2007-07-05 MX MX2015013326A patent/MX366319B/es unknown
- 2007-07-05 NZ NZ573732A patent/NZ573732A/en unknown
- 2007-07-05 KR KR1020147017714A patent/KR20140093291A/ko not_active Ceased
- 2007-07-05 AT AT07799337T patent/ATE524447T1/de active
- 2007-07-05 CA CA2656622A patent/CA2656622C/en active Active
- 2007-07-05 MX MX2019008117A patent/MX377920B/es unknown
- 2007-07-05 ES ES07799337T patent/ES2372774T3/es active Active
- 2007-07-05 MY MYPI20090024A patent/MY147364A/en unknown
- 2007-07-05 CN CN2007800330851A patent/CN101578273B/zh active Active
- 2007-07-05 NZ NZ597647A patent/NZ597647A/xx unknown
- 2007-07-05 BR BR122013028012A patent/BR122013028012B8/pt active IP Right Grant
- 2007-07-05 MX MX2008016202A patent/MX2008016202A/es active IP Right Grant
- 2007-07-05 CN CN2012101841274A patent/CN102816124A/zh active Pending
- 2007-07-05 ES ES11166125.2T patent/ES2554252T3/es active Active
- 2007-07-05 KR KR1020127011042A patent/KR101495408B1/ko active Active
- 2007-07-05 SG SG2013019468A patent/SG188905A1/en unknown
- 2007-07-05 ES ES11166123.7T patent/ES2554228T3/es active Active
- 2007-07-05 DK DK11166125.2T patent/DK2402325T3/en active
- 2007-07-05 SG SG2012082871A patent/SG185980A1/en unknown
- 2007-07-05 PL PL11166125T patent/PL2402325T3/pl unknown
- 2007-07-05 EP EP15178003.8A patent/EP2966065A3/en not_active Withdrawn
- 2007-07-05 BR BRPI0713923A patent/BRPI0713923B8/pt active IP Right Grant
- 2007-07-05 AU AU2007269060A patent/AU2007269060B2/en active Active
- 2007-07-05 SI SI200730780T patent/SI2049501T1/sl unknown
- 2007-07-05 PT PT07799337T patent/PT2049501E/pt unknown
- 2007-07-05 RU RU2009103900/04A patent/RU2478632C2/ru active
- 2007-07-05 SI SI200731699T patent/SI2402325T1/sl unknown
- 2007-07-05 PL PL07799337T patent/PL2049501T3/pl unknown
- 2007-07-05 JP JP2009518636A patent/JP5266216B2/ja active Active
- 2007-07-05 IN IN2886KON2014 patent/IN2014KN02886A/en unknown
- 2007-07-05 SG SG10201802127UA patent/SG10201802127UA/en unknown
- 2007-07-05 KR KR1020157010625A patent/KR20150051240A/ko not_active Ceased
- 2007-07-05 SG SG2012063863A patent/SG184706A1/en unknown
- 2007-07-05 EP EP11166123.7A patent/EP2399909B1/en active Active
- 2007-07-05 HR HR20110908T patent/HRP20110908T1/hr unknown
- 2007-07-05 KR KR1020137031899A patent/KR101578877B1/ko active Active
- 2007-07-05 KR KR1020097002395A patent/KR101178672B1/ko active Active
- 2007-07-05 CA CA2836316A patent/CA2836316A1/en not_active Abandoned
- 2007-07-05 EP EP07799337A patent/EP2049501B1/en active Active
- 2007-07-05 HU HUE11166125A patent/HUE026237T2/en unknown
- 2007-07-05 RS RS20110551A patent/RS52212B/sr unknown
- 2007-07-06 AR ARP070103033A patent/AR061842A1/es not_active Application Discontinuation
- 2007-07-06 TW TW096124780A patent/TWI402266B/zh active
- 2007-07-06 CL CL200701993A patent/CL2007001993A1/es unknown
- 2007-07-06 TW TW102117449A patent/TW201332994A/zh unknown
2008
- 2008-12-17 MX MX2011010569A patent/MX337843B/es unknown
- 2008-12-18 IL IL196028A patent/IL196028A/en active IP Right Grant
2009
- 2009-01-05 ZA ZA200900070A patent/ZA200900070B/xx unknown
- 2009-02-03 MA MA31609A patent/MA31655B1/fr unknown
- 2009-02-04 CO CO09010508A patent/CO6150161A2/es unknown
- 2009-02-05 CR CR10600A patent/CR10600A/es unknown
- 2009-02-05 NO NO20090581A patent/NO342346B1/no unknown
2011
- 2011-12-08 CY CY20111101222T patent/CY1112117T1/el unknown
2012
- 2012-12-20 RU RU2012155606/04A patent/RU2012155606A/ru not_active Application Discontinuation
2013
- 2013-02-19 JP JP2013029956A patent/JP5836294B2/ja active Active
- 2013-06-26 JP JP2013133983A patent/JP2013177470A/ja active Pending
- 2013-12-05 AR ARP130104510A patent/AR093810A2/es unknown
2014
- 2014-09-16 JP JP2014188238A patent/JP2014231530A/ja not_active Withdrawn
2015
- 2015-09-20 IL IL241705A patent/IL241705A0/en unknown
2017
- 2017-08-25 AR ARP170102366A patent/AR109424A2/es active IP Right Grant

Also Published As

Publication number	Publication date
WO2008006040A1 (en)	2008-01-10
SG184706A1 (en)	2012-10-30
RU2478632C2 (ru)	2013-04-10
CN102816124A (zh)	2012-12-12
NZ573732A (en)	2012-03-30
MX377920B (es)	2025-03-11
IN2014KN02886A (2)	2015-05-08
JP2013091670A (ja)	2013-05-16
PL2049501T3 (pl)	2012-02-29
AR109424A2 (es)	2018-11-28
KR101578877B1 (ko)	2016-02-22
BRPI0713923A2 (pt)	2013-07-02
SI2402325T1 (sl)	2015-12-31
MX337843B (es)	2016-03-22
RS52212B (sr)	2012-10-31
DK2049501T3 (da)	2011-12-12
KR20140093291A (ko)	2014-07-25
CA2836316A1 (en)	2008-01-10
HUE026237T2 (en)	2016-06-28
PL2402325T3 (pl)	2016-01-29
HK1126768A1 (en)	2009-09-11
JP2009542723A (ja)	2009-12-03
MA31655B1 (fr)	2010-09-01
HRP20110908T1 (hr)	2012-02-29
NZ610633A (en)	2014-12-24
CL2007001993A1 (es)	2008-06-20
CN101578273B (zh)	2012-11-14
NO342346B1 (no)	2018-05-07
MX366319B (es)	2019-07-05
IL241705A0 (en)	2015-11-30
BRPI0713923B8 (pt)	2021-05-25
EP2402325B1 (en)	2015-08-26
CA2656622A1 (en)	2008-01-10
HK1160134A1 (en)	2012-08-10
IL196028A0 (en)	2009-09-01
BR122013028012B1 (pt)	2021-04-06
EP2966065A2 (en)	2016-01-13
ES2554228T3 (es)	2015-12-17
EP2399909B1 (en)	2015-08-26
MX2008016202A (es)	2009-02-11
MY147364A (en)	2012-11-30
TW200817373A (en)	2008-04-16
UA95641C2 (xx)	2011-08-25
SI2049501T1 (sl)	2012-01-31
JP2014231530A (ja)	2014-12-11
BR122013028012B8 (pt)	2021-05-25
TWI402266B (zh)	2013-07-21
MX2019008117A (es)	2019-09-04
NZ597647A (en)	2013-08-30
KR20090030333A (ko)	2009-03-24
BR122013028005B1 (pt)	2021-04-06
TW201332994A (zh)	2013-08-16
CY1112117T1 (el)	2015-11-04
DK2402325T3 (en)	2015-12-07
KR20150051240A (ko)	2015-05-11
AR061842A1 (es)	2008-09-24
BRPI0713923B1 (pt)	2020-09-29
RU2012155606A (ru)	2014-06-27
AR093810A2 (es)	2015-06-24
EP2049501B1 (en)	2011-09-14
EP2399909A1 (en)	2011-12-28
HK1160638A1 (en)	2012-08-10
AU2007269060A1 (en)	2008-01-10
EP2049501A1 (en)	2009-04-22
ES2554252T3 (es)	2015-12-17
EP2402325A2 (en)	2012-01-04
BR122013028005B8 (pt)	2021-05-25
JP2013177470A (ja)	2013-09-09
CN101578273A (zh)	2009-11-11
CA2656622C (en)	2017-09-12
ZA200900070B (en)	2010-03-31
KR20130141717A (ko)	2013-12-26
SG10201802127UA (en)	2018-04-27
SG188905A1 (en)	2013-04-30
IL196028A (en)	2017-02-28
KR20130029364A (ko)	2013-03-22
JP5836294B2 (ja)	2015-12-24
PT2049501E (pt)	2011-12-30
CR10600A (es)	2009-02-20
NO20090581L (no)	2009-04-06
EP2966065A3 (en)	2016-03-02
EP2402325A3 (en)	2012-06-13
JP5266216B2 (ja)	2013-08-21
ES2372774T3 (es)	2012-01-26
KR101495408B1 (ko)	2015-02-25
RU2009103900A (ru)	2010-08-20
AU2007269060B2 (en)	2014-02-20
ATE524447T1 (de)	2011-09-15
KR101178672B1 (ko)	2012-09-07
SG185980A1 (en)	2012-12-28

Publication	Publication Date	Title
CO6150161A2 (es)	2010-04-20	Ciclopenta [d] pirimidinas hidroxiladas y metoxiladas como inhibidores de la proteina kinasa akt
CO6160229A2 (es)	2010-05-20	Ciclopenta [d] pirimidinas como inhibidores de proteina quinasa akt
AR070136A1 (es)	2010-03-17	Pirimidil ciclopentanos como inhibidores de la akt proteina quinasa
PE20221010A1 (es)	2022-06-15	Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
CY1121699T1 (el)	2020-07-31	Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
PE20250157A1 (es)	2025-01-22	Compuestos de modulacion de kras g12d
AR072545A1 (es)	2010-09-08	Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias.
CO5611147A2 (es)	2006-02-28	Derivados de nicotinamida utiles como inhibidores p38
PE20120229A1 (es)	2012-04-04	Compuestos heterociclicos como inhibidores de proteasa aspartica
MX2009005449A (es)	2009-06-02	Compuesto heteromonociclico y uso del mismo.
AR042042A1 (es)	2005-06-08	Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
NO20092692L (no)	2009-09-16	MAPK/ERK kinaseinhibitorer
AR046080A1 (es)	2005-11-23	Piridinonas sustituidas
CO5611110A2 (es)	2006-02-28	Mimeticos de glucocorticoides, procedimientos para su preparacion, composiciones farmaceuticas y usos de los mismos
AR067413A1 (es)	2009-10-07	Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
PE20121815A1 (es)	2013-02-03	Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
PE20121431A1 (es)	2012-11-10	Derivados de pirimidina como inhbidores de la enzima cinasa ptk2
AR054560A1 (es)	2007-06-27	Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR085960A1 (es)	2013-11-06	1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR075084A1 (es)	2011-03-09	Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
MX2010004893A (es)	2010-05-19	Compuesto heterociclico y composicion farmaceutica del mismo.
AR053120A1 (es)	2007-04-25	Aminopiridinas como inhibidores de beta secretasa
AR074540A1 (es)	2011-01-26	Compuestos de morfolinona como inhibidores del factor ixa
PH12017501655B1 (en)	2022-07-22	Morphinan derivative
HRP20080493T3 (hr)	2009-02-28	Supstituirani kinolinski derivati kao mitotski inhibitori kinezina